3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
10
OTHER
8
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Breast
1
Conditions
Wounds and Injuries
1
Head and Neck Neoplasms
1
Cancer Pain
1
Breast Neoplasms
1
Interventions
Capecitabine
28
apatinib
26
Oxaliplatin
24
Cisplatin
24
tislelizumab
23
Gemcitabine
23
Irinotecan
19
Paclitaxel
18
Carboplatin
18
Docetaxel
15
Bevacizumab
15
Fluorouracil
14
Drug Therapy
13
Cyclophosphamide
11
pembrolizumab
10
camrelizumab
10
Vinorelbine
9
Radiation
9
S 1 (combination)
8
Leucovorin
8
Cetuximab
8
toripalimab
7
sintilimab
7
Rituximab
7
Erlotinib Hydrochloride
7
pyrotinib
6
Gefitinib
6
Albumin-Bound Paclitaxel
6
fludarabine
5
anlotinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER_GOV
×
Gels
×
Clear all
NCT05800834
2023-09-28
MorphineGEL
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
106 enrolled